Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crizotinib + denosumab
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy consisting of crizotinib, a tyrosine kinase inhibitor targeting ALK, ROS1, and MET, and denosumab, a RANK ligand inhibitor. This combination has shown potential efficacy in treating ALK-positive non-small cell lung cancer, particularly in cases with bone metastases. A case report has demonstrated response of both primary tumor and metastases in a patient with metastatic adenocarcinoma of the lung harboring an ALK gene translocation when treated with denosumab, suggesting a possible link between ALK and RANK signaling pathways.
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on crizotinib + denosumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crizotinib + denosumab.